Pegaptanib sodium injection (brand name Macugen) is an anti-angiogenic medicine for the treatment of neovascular (wet) age-related macular degeneration...
12 KB (1,231 words) - 17:27, 2 July 2024
below the retinal pigment epithelium. Angiogenesis inhibitors include pegaptanib, ranibizumab and bevacizumab (known by a variety of trade names, such...
7 KB (833 words) - 05:58, 1 January 2024
Cochrane Systematic Review studied the effectiveness of ranibizumab and pegaptanib, on patients who have macular edema caused by central retinal vein occlusion...
14 KB (1,671 words) - 06:48, 24 August 2024
studied the effectiveness of two anti-VEGF treatments, ranibizumab and pegaptanib, on patients with macular edema caused by CRVO. Participants on both treatment...
16 KB (1,554 words) - 03:45, 22 August 2024
Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib...
68 KB (5,999 words) - 20:41, 31 August 2024
evidence supports the use of anti-VEGF antibodies, such as bevacizumab or pegaptanib which seems to improve outcomes when used in conjunction with laser therapy...
19 KB (2,059 words) - 20:05, 20 July 2024
Chemokine Ligand 12 (CXCL2). An example of an RNA aptamer therapy includes Pegaptanib (aka Macugen ® ), the only FDA-approved RNA aptamer treatment. Originally...
77 KB (8,886 words) - 09:03, 10 June 2024
injection) – Pharmacologic stress agent for myocardial perfusion scan Macugen (pegaptanib sodium) – Anti-angiogenic – marketed with Gilead Sciences in the US and...
27 KB (2,449 words) - 21:35, 29 June 2024
Commercial products and companies based on aptamers include the drug Macugen (pegaptanib) and the clinical diagnostic company SomaLogic. The International Society...
60 KB (6,559 words) - 14:38, 19 June 2024
Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib...
149 KB (15,717 words) - 06:34, 13 August 2024
Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib...
42 KB (3,935 words) - 04:01, 30 April 2024
Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib...
17 KB (1,489 words) - 05:47, 7 April 2024
Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib...
35 KB (4,573 words) - 09:59, 28 August 2024
of the body. Drugs such as aflibercept, bevacizumab, ranibizumab, and pegaptanib can inhibit VEGF and control or slow those diseases. In 1970, Judah Folkman...
40 KB (4,580 words) - 05:24, 3 June 2024
Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib...
121 KB (13,799 words) - 18:32, 22 August 2024
Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib...
31 KB (3,430 words) - 05:24, 28 August 2024
approved antiangiogenic drugs for the treatment of neo-vascular AMD include pegaptanib and aflibercept. These anti-VEGF agents may be administered monthly or...
90 KB (9,840 words) - 22:49, 25 August 2024
Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib...
23 KB (1,801 words) - 21:23, 31 August 2024
Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib...
13 KB (1,177 words) - 00:03, 12 August 2024
Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib...
92 KB (8,671 words) - 18:15, 17 August 2024
Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib...
43 KB (4,651 words) - 13:41, 27 July 2024
Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib...
24 KB (1,710 words) - 19:18, 30 August 2024
Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib...
24 KB (2,275 words) - 00:45, 12 July 2024
Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib...
73 KB (6,440 words) - 02:59, 3 September 2024
Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib...
5 KB (412 words) - 23:17, 19 June 2023
Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib...
11 KB (934 words) - 23:22, 24 August 2024
Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib...
22 KB (1,993 words) - 23:37, 23 March 2024
Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib...
10 KB (1,179 words) - 18:31, 8 August 2024
to combat anemia associated with chronic kidney disease (Roche, 2007) Pegaptanib (Macugen) – used to treat neovascular age-related macular degeneration...
27 KB (2,984 words) - 07:20, 22 August 2024
Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib Semaxanib Sorafenib Sunitinib Toceranib Tivozanib...
43 KB (5,251 words) - 10:44, 24 June 2024